desktop scale image mobile scale image
desktop header thumbnail mobile header thumbnail

Information for HCP’s

If you’re an HCP, here’s where you’ll find more information about MolluDab®, its application, clinical efficacy and the benefits of using it to treat molluscum contagiosum in your patients. Alternatively, if you’d like to know more about any aspect of MolluDab®, you can get in touch with our team here.

References

  1. Centres for Disease Control and Prevention. Molluscum Contagiosum. https://www.cdc.gov/poxvirus/molluscum-contagiosum/index.html (accessed 03 June 2019)
  2. Pannell RS, Fleming DM and Cross KW. The incidence of Molluscum contagiosum, scabies and lichen planus. Epidemiol. Infect. 2005, 133. 985-991
  3. Romiti R, Ribeiro AP, Romiti N. Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of Molluscum contagiosum. Pediatr Dermatol. 2000 Nov-Dec; 17(6):493.
  4. Jansen T, Romiti R, Dissemond J and Grabbe S. Evaluation of the Efficacy and Tolerability of 5% Potassium Hydroxide in the Treatment of Molluscum Contagiosum in Childhood. Akt Dermatol. (German, abstract in English translated article available on request -see contact form) 2007; 33: 210-215
  5. Rajouria EA, Amatya A and Karn D. Comparative Study of 5% Potassium Hydroxide Solution Versus 0.05% Tretinoin Cream for Molluscum Contagiosum in Children. Kathmandu Univ Med J. 2011:3(64):291-4
 

This section of the website has been created to provide UK healthcare professionals with information regarding MolluDab®

If you are not a UK healthcare professional, please click here to return to the public section of the website.

AL/3775d/05.19/0.001. Date of preparation: May 2019